Equally, markers such as LGALSBP3 (predominant in grade I and II) and TGFΒ1, DAG1, and LOXL2 (predominant in grade I and II) may be able to provide further choice insights between operative and medical management of DCIS. The gene discussed is LOXL2; the disease is ductal breast carcinoma in situ.